This is a step-by-step stock review to answer the question, is Vaxart (VXRT) stock a good buy?
This article will teach you how to use the 4Ms of investing. This will be a detailed walkthrough to show you how the 4Ms work and why they are important. If you are interested, you can log into Tykr to use the 4M Confidence Booster (Powered by OpenAI) which will allow you to complete a 4M Analysis in less than 60 seconds.
What are the 4Ms?
- MOS (Margin of Safety) – The MOS is the math part of investing which includes the Summary, Score, and MOS (Margin of Safety).
- Meaning – The meaning is the business model and how scalable the revenue streams are.
- Moat – The moat is how the business compares to other companies in the same Sector and Industry.
- Management – The management is the track record of the CEO.
What 4M score are we going for?
- 80-100 = High confidence – Yay! You should have high confidence buying this stock. It passes all 4M!
- 60-79 = Moderate confidence – Alert! There may be better stocks in the market. Only buy this stock if you truly believe the company will improve!
- 0-59 = Low confidence – Warning! There are better stocks in the market. Due to the low score, you should consider looking at other stocks.
Table of Contents
The following links will direct you to key topics to help answer the question, is Vaxart (VXRT) stock a good buy?
1. Vaxart Company History
When investing in stocks, it’s important to know the company’s history. This helps us understand the various revenue streams, if they acquired other companies, how they grew through difficult times, and how they separated themselves from the competition.
- Founded: Vaxart was founded in 2004 and is headquartered in South San Francisco, California.
- Focus: Specializes in developing oral recombinant vaccines using a proprietary oral vaccine platform.
- Initial Public Offering: Vaxart went public in 2017 through a reverse merger with Aviragen Therapeutics.
- Early Developments: Initially focused on influenza vaccines, leveraging its oral tablet vaccine technology.
- COVID-19 Response: In 2020, Vaxart shifted focus to develop an oral COVID-19 vaccine candidate. The potential advantages include ease of administration and distribution without the need for refrigeration.
- Partnerships: Collaborated with various organizations, including the Biomedical Advanced Research and Development Authority (BARDA), to advance vaccine development.
- Pipeline: Besides COVID-19, Vaxart is working on vaccines for norovirus, seasonal influenza, and RSV (Respiratory Syncytial Virus).
- Technology: Uses a vector-based platform that employs non-replicating adenovirus to deliver vaccine antigens.
- Clinical Trials: Conducted multiple clinical trials for its vaccine candidates, with ongoing research and development to enhance efficacy and safety.
- Recognition: Gained significant attention during the COVID-19 pandemic for its innovative approach to vaccine delivery.
Vaxart’s innovative oral vaccine platform aims to revolutionize vaccine administration, making it easier and more accessible, while addressing critical public health needs.
2. MOS (Margin Of Safety)
When investing in a company, the first step is to look at the financials. Fortunately, Tykr does this for us automatically. The higher the score, the stronger the financials and the safer the investment. The higher the MOS, the higher the potential returns you can make.
- Summary:Overpriced
- Score: 39
- MOS: 23%
To see the most up-to-date Summary, Score, and MOS, please log into Tykr.
3. Meaning
When investing in a company, it’s important to know how a company makes money. A mature business model has multiple streams of revenue which allow the company to weather downturns in the economy.
Here is how Vaxart makes money:
- Vaccine Development: Revenue from developing and commercializing vaccines, including oral vaccines for various diseases.
- Partnerships and Grants: Income from collaborations, partnerships, and government grants for research and development.
- Licensing Agreements: Earnings from licensing its technology and vaccine candidates to other pharmaceutical companies.
- Clinical Trials: Funding from clinical trials conducted to advance its vaccine products and technology.
Here are a few of the other companies that Vaxart has acquired over the years. This is important because a company will use a “Buy before build” philosophy to go to market faster and add additional streams of revenue. A company with more revenue streams has a more stable business model. Keep in mind, that most companies don’t build new software because it takes too long to go to market and generate revenue.
- Aviragen Therapeutics
4. Moat
When investing in a company, it’s important to understand how a company ranks against other companies in the same sector and industry. Based on the Score, here is how Vaxart , Inc. stacks up against other companies.
- Arcellx, Inc.(ACLX) – 89
- Amylyx Pharmaceuticals, Inc.(AMLX) – 89
- United Therapeutics Corporation.(UTHR) – 89
- Protagonist Therapeutics, Inc.(PTGX) – 84
- Genmab A/S.(GMAB) – 78
- Vaxart, Inc.(VXRT) – 39
To see the most up-to-date Summary, Score, and MOS and each stock, please log into Tykr.
5. Management
When investing in a company, it’s important to understand who the CEO is, what they have accomplished in the past, and how they have helped this company grow. Good leaders typically have stronger cultures, less turnover, and better returns in the stock market.
- Developed Oral Vaccine Platform: Andrei Floroiu Led the development of Vaxart’s oral vaccine platform, focusing on ease of administration and increased accessibility.
- COVID-19 Vaccine Candidate: Advanced Vaxart’s COVID-19 oral vaccine candidate through clinical trials, aiming for an easy-to-administer alternative to traditional injections.
- Strategic Partnerships: Established important partnerships, including collaborations with biomedical research institutions, to enhance vaccine research and development.
- Funding and Investment: Secured significant funding and investment to support the company’s research, development, and operational efforts.
- Market Growth: Contributed to a notable increase in Vaxart’s market presence and stock performance during his tenure.
- Public Health Impact: Focused on creating vaccines that could potentially impact global public health by addressing diseases with high unmet needs.
6. 4M Score
All of our homework on this company leads up to the 4M Score. A lot of investors only look at the numbers. Yes, it’s important to look at the first M (MOS) which is the math part of investing but it’s also important to look past the numbers and also look at the Meaning, Moat, and Management. If all 4Ms pass, we should have high confidence in buying this stock.
What 4M score are we going for?
- 80-100 = High confidence – Yay! You should have high confidence buying this stock. It passes all 4M!
- 60-79 = Moderate confidence – Alert! There may be better stocks in the market. Only buy this stock if you truly believe the company will improve!
- 0-59 = Low confidence – Warning! There are better stocks in the market. Due to the low score, you should consider looking at other stocks.
👉 The 4M Score of Vaxart (VXRT) is 41/100.
To see the most up-to-date 4M Score, please log into Tykr.
7. Is Vaxart (VXRT) stock a good buy?
Some of the top questions investors can have is Vaxart (VXRT) stock a good buy or should I buy Vaxart (VXRT) stock?
Vaxart could be an intriguing investment for those interested in innovative vaccine technologies. The company is focused on developing oral vaccines, which offer a novel and potentially more accessible approach compared to traditional injections. Vaxart’s strategic partnerships and research into COVID-19 and other vaccines highlight its potential for growth. However, it’s important to note that Vaxart is a smaller, emerging biotech firm, which can come with higher risks. The company faces challenges such as regulatory hurdles and competition from larger firms. As with any investment, weigh Vaxart’s potential for innovation against the risks and your personal investment goals.
—
To truly know if Vaxart is a good stock to buy or sell, we recommend you log into Tykr. Within seconds you can see the Summary, Score, MOS, and 4M Score.
If you found this stock review interesting, you may also like this review on AMD.